By Investing.com Staff
After-Hours Stock Movers:
Relmada Therapeutics (NASDAQ:RLMD) 37% LOWER; announced results of the RELIANCE I study (REL-1017-301), evaluating REL-1017 as an adjunctive treatment for Major Depressive Disorder (MDD). The same factors that negatively affected the previously announced results from the RELIANCE III study, a limited number of high enrolling sites with unplausible placebo response, also affected RELIANCE I and the study did not achieve its primary endpoint, which was a statistically significant improvement in depression symptoms compared to placebo as measured by the Montgomery-Asberg Depression Rating Scale (MADRS) on Day 28. RELIANCE I evaluated the use of REL-1017 in addition to a standard antidepressant for patients who had inadequate response to at least one and up to three standard antidepressant therapies.
Rent the Runway Inc (NASDAQ:RENT) 25% HIGHER; reported Q3 EPS of ($0.56), $0.15 better than the analyst estimate of ($0.71). Revenue for the quarter came in at $77.4 million versus the consensus estimate of $79.88M. Rent the Runway sees Q4 2023 revenue of $72-74M, versus the consensus of $71.66M. Rent the Runway sees FY2023 revenue of $293-295M, versus the consensus of $287.55M.
Cutera (NASDAQ:CUTR) 15% LOWER; intends to offer, subject to market conditions and other factors, $100M aggregate principal amount of convertible senior notes due 2029.
HashiCorp Inc (NASDAQ:HCP) 9% HIGHER; reported Q2 EPS of ($0.13), $0.19 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $125.3M versus the consensus estimate of $111.09M. HCP, Inc. sees Q3 2022 EPS of ($0.23)-($0.21), versus the consensus of ($0.30). HCP, Inc. sees Q3 2022 revenue of $123-125M, versus the consensus of $119.93M. HCP, Inc. sees FY2022 EPS of ($0.71)-($0.69), versus the consensus of ($0.96). HCP, Inc. sees FY2022 revenue of $463-465M, versus the consensus of $445.53M.
Chefs' Warehouse Inc (NASDAQ:CHEF) 8% LOWER; announced that it intends to offer, subject to market conditions and other factors, $250M aggregate principal amount of its convertible senior notes due 2028.